In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuroSystec Corp.

Latest From NeuroSystec Corp.

Otonomy Sustained-Release Gels May Solve Ear Med Delivery Problems

Otonomy has moved two candidates into registration trials for middle and inner ear disorders and plans to have a third ready for the clinic next year.

BioPharmaceutical Clinical Trials

AAO Highlights: Back (of the Eye) to the Future

The 2009 meeting of the American Academy of Ophthalmology showcased the latest developments in cataract/refractive surgery, glaucoma, retina, and other ophthalmic subspecialties. The cataract/refractive surgery market has been under significant economic pressure recently due to a recessionary drop in elective ophthalmic procedures. However, evolving treatments for "back of the eye" conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, are making significant inroads toward improved patient outcomes for these common and devastating diseases and continue to energize the retina products market.

Medical Device

Selected Start-Ups (5/05)

In Vivo briefly summarizes the technologies of these recently founded companies: Anthera Pharmaceuticals, Genistent Medical, NeuroSystec, Tengion, T-Shift and Vaxon Biotech.

See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Medical Devices
    • Implantable Devices
UsernamePublicRestriction

Register